AVCN-583601 is under clinical development by Avicanna and currently in Phase III for Epidermolysis Bullosa. According to GlobalData, Phase III drugs for Epidermolysis Bullosa have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AVCN-583601’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AVCN-583601 overview

AVCN-583601 is under development for the treatment of epidermolysis bullosa. The drug candidate is a cannabinoid-based product and acts by targeting cannabinoid receptors CB1 and CB2. It is developed based on avicanna platform. It was administered through topical route.

Avicanna overview

Avicanna is a company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products

For a complete picture of AVCN-583601’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.